Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL4131431 | 0.90 | KDM4E (0.44) | KMT2ALMNAHTTSMN1; SMN2HDAC4 | |
| SCHEMBL4127400 | 0.89 | ACHE (0.40) | ACHECHRM4BCHELMNAHTT | |
| Dimethylamine SCHEMBL4114401 | 0.88 | ACHE (0.54) | ACHECHRM4KMT2ABCHE | |
| Dimethylamine SCHEMBL4121979 | 0.88 | ACHE (0.53) | ACHECHRM4BCHE | |
| SCHEMBL4126753 | 0.87 | ACHE (0.38) | ACHECHRM4MCHR1BCHELMNA | |
| Dimethylamine SCHEMBL4135890 | 0.85 | ACHE (0.41) | ACHEKMT2ABCHESMN1; SMN2 | |
| Dimethylamine SCHEMBL4129762 | 0.85 | ACHE (0.41) | ACHEKMT2ABCHELMNA | |
| Dimethylamine SCHEMBL4121726 | 0.82 | ACHE (0.42) | ACHEBCHE | |
| SCHEMBL4126138 | 0.81 | ACHE (0.35) | ACHECHRM4KMT2ABCHEKCNH2 | |
| Dimethylamine SCHEMBL4131966 | 0.81 | ACHE (0.43) | ACHECHRM4KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | ACHE 3716/4885CHRM4 234/4885KMT2A 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.